SIA FUNDS, EL FONDO QUE CONFÍA EN GRÍFOLS SE POSICIONA EN CONTRA DE LA OPA .
12 febrero 2020
With an FDA priority review, Novartis hopes its capmatinib can beat Merck KGaA’s tepotinib to become the first targeted drug specifically approved to treat MET exon 14 skipping-mutated "" NON Small Cell Lung Cancer. (Novartis) .
‹
›
Inicio
Ver versión web